Times names Dr. Paul Sanberg in Top Ten People to Watch in 2010
USF’s Paul Sanberg, PhD, DSc, was listed in the Jan. 10 edition of the St. Petersburg Times as one of 10 people to watch in 2010 who will influence local business.
Times business columnist Robert Trigaux compiled the Top Ten People to Watch, which ranked Dr. Sanberg ninth, citing the following:
“We don’t know yet if the antidepressant alternative drug TC-5214 developed by Sanberg, 55, and his fellow USF researchers will be a blockbuster with university royalties akin to Gatorade for the University of Florida or cancer drug Taxol for Florida State University. But the early signs are encouraging, given last month’s major licensing deal between global pharmaceutical company AstraZeneca PLC and Targacept Inc. This is, of course, is what university researchers dream of. And it is what keeps universities like USF — still young, still looking for respect and always looking for major new revenue sources — forever on the hunt.”
Check out the Times article to see the entire listing. Karen Holbrook, PhD, USF vice president for research and innovation was ranked number 5.
Dr. Sanberg, who joined USF in 1992, is a Distinguished University Professor at USF and director of the USF Center of Excellence for Aging and Brain Repair. He is also associate vice president and associate dean for USF Biotechnology Development. Dr. Sanberg is currently chairman and founder of Saneron CCEL Therapeutics, Inc. (a USF spin-out company based in Tampa), which is involved in cell therapy for degenerative disorders. He is editor-in-chief of Cell Transplantation, executive director of the American Society for Neural Transplantation and Repair, and past president of the Cell Transplant Society, and others. He is the author of more than 400 scientific publications, including 13 books.
Dr. Paul Sanberg (right) led a tour for Florida Governor Charlie Crist when he visited USF in 2007.